Abeprazan hydrochloride

• CAT Number: I017249
• CAS Number: 1902954-87-3
• Molecular Formula: C19H18ClF3N2O3S
• Molecular Weight: 446.87
• Purity: ≥95%
• Synonyms: 1-[5-(2,4-difluorophenyl)-1-(3-fluorophenyl)sulfonyl-4-methoxypyrrol-3-yl]-N-methylmethanamine;hydrochloride
• InChI: InChI=1S/C19H17F3N2O3S.ClH/c1-23-10-12-11-24(28(25,26)15-5-3-4-13(20)8-15)18(19(12)27-2)16-7-6-14(21)9-17(16)22;/h3-9,11,23H,10H2,1-2H3;1H
• InChIKey: BOHTZYBQQDVIRI-UHFFFAOYSA-N
• SMILES: CNCC1=CN(C(=C1OC)C2=C(C=C(C=C2)F)F)S(=O)(=O)C3=CC=CC(=C3)F.Cl

Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1].
The mechanism of action of Abeprazan hydrochloride is reversibly binding to H+, K+‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation[1].
Abeprazan hydrochloride (DWP14012 hydrochloride) inhibits acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion is equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models[1].

Reference

[1]. Sunwoo J, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018 Jul;48(2):206-218.
 [Content Brief]